Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer

BACKGROUND: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (tac) compared with 5-fluorouracil, doxorubicin, and c...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Mittmann, N., Verma, S., Koo, M., Alloul, K., Trudeau, M.
格式: Artigo
語言:Inglês
出版: Multimed Inc. 2010
主題:
Practice Guidelines
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826781/
https://ncbi.nlm.nih.gov/pubmed/20179798
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍